NO307786B1 - Itrakonazol- og saperkonazol-stereoisomerer - Google Patents
Itrakonazol- og saperkonazol-stereoisomererInfo
- Publication number
- NO307786B1 NO307786B1 NO943450A NO943450A NO307786B1 NO 307786 B1 NO307786 B1 NO 307786B1 NO 943450 A NO943450 A NO 943450A NO 943450 A NO943450 A NO 943450A NO 307786 B1 NO307786 B1 NO 307786B1
- Authority
- NO
- Norway
- Prior art keywords
- itraconazole
- saperconazole
- stereoisomers
- pharmaceutically acceptable
- stereoisomer
- Prior art date
Links
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 title abstract 2
- 229960004130 itraconazole Drugs 0.000 title abstract 2
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical class O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 title 1
- 206010017533 Fungal infection Diseases 0.000 abstract 1
- 208000031888 Mycoses Diseases 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85364892A | 1992-03-18 | 1992-03-18 | |
| PCT/EP1993/000552 WO1993019061A1 (en) | 1992-03-18 | 1993-03-10 | Itraconazole and saperconazole stereoisomers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO943450D0 NO943450D0 (no) | 1994-09-16 |
| NO943450L NO943450L (no) | 1994-11-11 |
| NO307786B1 true NO307786B1 (no) | 2000-05-29 |
Family
ID=25316567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO943450A NO307786B1 (no) | 1992-03-18 | 1994-09-16 | Itrakonazol- og saperkonazol-stereoisomerer |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5998413A (cs) |
| EP (1) | EP0631578B1 (cs) |
| KR (1) | KR100243534B1 (cs) |
| AT (1) | ATE201408T1 (cs) |
| AU (1) | AU665988B2 (cs) |
| CA (1) | CA2117651C (cs) |
| CZ (1) | CZ286619B6 (cs) |
| DE (1) | DE69330248T2 (cs) |
| DK (1) | DK0631578T3 (cs) |
| ES (1) | ES2158859T3 (cs) |
| FI (1) | FI113175B (cs) |
| GR (1) | GR3036368T3 (cs) |
| HU (1) | HU221189B1 (cs) |
| NO (1) | NO307786B1 (cs) |
| NZ (1) | NZ249494A (cs) |
| PL (1) | PL172358B1 (cs) |
| PT (1) | PT631578E (cs) |
| RU (1) | RU2127733C1 (cs) |
| SK (1) | SK283118B6 (cs) |
| WO (1) | WO1993019061A1 (cs) |
| ZA (1) | ZA931906B (cs) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6096094A (en) * | 1993-01-27 | 1994-08-15 | Georgetown University | Method and composition employing (2r,4s) itraconazole |
| PH31594A (en) * | 1993-09-30 | 1998-11-03 | Janssen Pharmaceutica Nv | Oral formulations on an antifungal. |
| TW438601B (en) * | 1994-05-18 | 2001-06-07 | Janssen Pharmaceutica Nv | New mucoadhesive emulsion compositions and a process for the preparation thereof |
| US5486625A (en) * | 1994-07-08 | 1996-01-23 | Schering Corporation | Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents |
| ES2112151B1 (es) * | 1995-03-17 | 1999-09-16 | Menarini Lab | Nuevos compuestos homoquirales para la preparacion de ketoconazol, terconazol y antifungicos relacionados, procedimiento para su fabricacion y utilizacion de los mismos. |
| ES2243994T5 (es) | 1996-04-19 | 2009-10-29 | Grifols Inc. | Procedimiento para la inactivacion virica de proteinas de la sangre liofilizadas. |
| KR19990044257A (ko) * | 1996-05-20 | 1999-06-25 | 디르크 반테 | 생체이용율이 개선된 항진균성 조성물 |
| JP2001504464A (ja) * | 1996-11-12 | 2001-04-03 | セプラコール，インク． | ２ｒ，４ｓ，ｓ，ｒ―および２ｓ，４ｒ，ｓ，ｒ―ヒドロキシイトラコナゾール |
| WO1998021204A1 (en) * | 1996-11-12 | 1998-05-22 | Sepracor, Inc. | 2r,4s,s,s- and 2s,4r,s,s-hydroxyitraconazole |
| WO1998020876A1 (en) * | 1996-11-12 | 1998-05-22 | Sepracor Inc. | Use of cis-hydroxyitraconazole in order to avoid side-effects of itraconazole and hydroxyintraconazole |
| JP2001504121A (ja) * | 1996-11-12 | 2001-03-27 | セプラコール，インク． | ２ｒ，４ｓ，ｒ，ｓ―および２ｓ，４ｒ，ｒ，ｓ―ヒドロキシイトラコナゾール―およびヒドロキシサパーコナゾール誘導体 |
| EP0938484A1 (en) * | 1996-11-12 | 1999-09-01 | Sepracor, Inc. | 2r,4s,r,r- and 2s,4r,r,r-hydroxyitraconazole |
| HU227744B1 (en) | 1997-02-11 | 2012-02-28 | Janssen Pharmaceutica Nv | Amino acid ester containing azole antifungals, process for their preparation, pharmaceuticals containing the same and intermediates |
| US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
| US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
| EP0957101A1 (en) * | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| US6497905B1 (en) | 1999-03-24 | 2002-12-24 | R.P. Scherer Technologies, Inc. | Aqueous solubility pharmaceutical formulations |
| KR100331529B1 (ko) * | 1999-06-16 | 2002-04-06 | 민경윤 | 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법 |
| US6932861B2 (en) | 2000-11-28 | 2005-08-23 | Fmc Corporation | Edible PGA coating composition |
| KR100438485B1 (ko) * | 2001-08-13 | 2004-07-09 | 한국디디에스제약 주식회사 | 아졸류 항진균제의 약제학적 조성물 |
| US7446107B2 (en) * | 2002-02-15 | 2008-11-04 | Transform Pharmaceuticals, Inc. | Crystalline forms of conazoles and methods of making and using the same |
| US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
| WO2003074474A2 (en) | 2002-03-01 | 2003-09-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
| US7078526B2 (en) * | 2002-05-31 | 2006-07-18 | Transform Pharmaceuticals, Inc. | CIS-itraconazole crystalline forms and related processes, pharmaceutical compositions and methods |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| CN100360117C (zh) | 2002-06-21 | 2008-01-09 | 转化医药公司 | 具有提高的溶出度的药物组合物 |
| KR100446256B1 (ko) * | 2002-07-11 | 2004-09-01 | 경동제약 주식회사 | 고 광학선택성을 가지는시스-2-(브로모메틸)-2-(2,4-디클로로페닐)-13-디옥소란-4-메틸알콜의 제조방법 |
| US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
| DK1912626T3 (en) | 2005-08-08 | 2016-08-01 | Abbvie Deutschland | Dosage forms with improved bioavailability |
| ES2571032T3 (es) | 2005-08-08 | 2016-05-23 | Abbvie Deutschland | Composiciones de itraconazol con biodisponibilidad mejorada |
| WO2007024971A2 (en) | 2005-08-22 | 2007-03-01 | The Johns Hopkins University | Hedgehog pathway antagonists to treat disease |
| EP2753179A4 (en) * | 2011-09-09 | 2015-03-04 | Univ Leland Stanford Junior | TOPICAL ITRACONAZOLE FORMULATIONS AND THEIR USE |
| CN102379844A (zh) * | 2011-10-31 | 2012-03-21 | 广州维美投资有限公司 | 一种伊曲康唑异构体注射剂 |
| CN105061411A (zh) * | 2015-06-23 | 2015-11-18 | 扬州艾迪生物科技有限公司 | 一种光学异构体2s,4r,2’s-伊曲康唑晶型及制备方法与应用 |
| CN106146480B (zh) * | 2016-07-18 | 2019-08-06 | 山东罗欣药业集团恒欣药业有限公司 | 一种伊曲康唑的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4287195A (en) * | 1978-07-14 | 1981-09-01 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles |
| US4490530A (en) * | 1981-01-14 | 1984-12-25 | Janssen Pharmaceutica N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| HU191101B (en) * | 1983-02-14 | 1987-01-28 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu | Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| GB8506792D0 (en) * | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
| US4916134A (en) * | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| FR2622198B1 (fr) * | 1987-10-21 | 1992-04-30 | Mero Rousselot Satia | Compositions granulees de polysaccharides a dissolution aqueuse instantanee, procede pour leur preparation et utilisation |
| US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| JP2792610B2 (ja) * | 1989-04-03 | 1998-09-03 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | シクロデキストリンの区域選択的置換 |
| GB8908250D0 (en) * | 1989-04-12 | 1989-05-24 | Fisons Plc | Formulations |
| US5214046A (en) * | 1989-07-27 | 1993-05-25 | Hoffmann-La Roche Inc. | Substituted aminoalkoxybenzene anti-fungicidal compositions and use |
| AU6096094A (en) * | 1993-01-27 | 1994-08-15 | Georgetown University | Method and composition employing (2r,4s) itraconazole |
-
1993
- 1993-03-10 CZ CZ19942215A patent/CZ286619B6/cs not_active IP Right Cessation
- 1993-03-10 HU HU9402656A patent/HU221189B1/hu not_active IP Right Cessation
- 1993-03-10 WO PCT/EP1993/000552 patent/WO1993019061A1/en not_active Ceased
- 1993-03-10 PL PL93305223A patent/PL172358B1/pl not_active IP Right Cessation
- 1993-03-10 ES ES93905338T patent/ES2158859T3/es not_active Expired - Lifetime
- 1993-03-10 SK SK1106-94A patent/SK283118B6/sk unknown
- 1993-03-10 AU AU36324/93A patent/AU665988B2/en not_active Ceased
- 1993-03-10 EP EP93905338A patent/EP0631578B1/en not_active Expired - Lifetime
- 1993-03-10 DE DE69330248T patent/DE69330248T2/de not_active Expired - Fee Related
- 1993-03-10 DK DK93905338T patent/DK0631578T3/da active
- 1993-03-10 AT AT93905338T patent/ATE201408T1/de not_active IP Right Cessation
- 1993-03-10 CA CA002117651A patent/CA2117651C/en not_active Expired - Fee Related
- 1993-03-10 NZ NZ249494A patent/NZ249494A/en not_active IP Right Cessation
- 1993-03-10 KR KR1019940702921A patent/KR100243534B1/ko not_active Expired - Fee Related
- 1993-03-10 PT PT93905338T patent/PT631578E/pt unknown
- 1993-03-10 RU RU94045798A patent/RU2127733C1/ru not_active IP Right Cessation
- 1993-03-17 ZA ZA931906A patent/ZA931906B/xx unknown
-
1994
- 1994-09-16 FI FI944311A patent/FI113175B/fi active
- 1994-09-16 NO NO943450A patent/NO307786B1/no unknown
-
1996
- 1996-07-09 US US08/676,531 patent/US5998413A/en not_active Expired - Fee Related
-
2001
- 2001-08-10 GR GR20010401224T patent/GR3036368T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US5998413A (en) | 1999-12-07 |
| HUT71835A (en) | 1996-02-28 |
| RU94045798A (ru) | 1996-07-20 |
| AU665988B2 (en) | 1996-01-25 |
| CZ286619B6 (cs) | 2000-05-17 |
| SK283118B6 (sk) | 2003-02-04 |
| FI944311A0 (fi) | 1994-09-16 |
| FI113175B (fi) | 2004-03-15 |
| PT631578E (pt) | 2001-11-30 |
| ATE201408T1 (de) | 2001-06-15 |
| CA2117651A1 (en) | 1993-09-30 |
| NZ249494A (en) | 1996-04-26 |
| CZ221594A3 (en) | 1995-01-18 |
| KR950700904A (ko) | 1995-02-20 |
| EP0631578B1 (en) | 2001-05-23 |
| FI944311L (fi) | 1994-09-16 |
| RU2127733C1 (ru) | 1999-03-20 |
| NO943450L (no) | 1994-11-11 |
| HU221189B1 (en) | 2002-08-28 |
| CA2117651C (en) | 2006-01-03 |
| ZA931906B (en) | 1994-09-17 |
| PL172358B1 (en) | 1997-09-30 |
| SK110694A3 (en) | 1995-04-12 |
| EP0631578A1 (en) | 1995-01-04 |
| HK1010729A1 (en) | 1999-06-25 |
| HU9402656D0 (en) | 1994-11-28 |
| DE69330248T2 (de) | 2002-03-21 |
| ES2158859T3 (es) | 2001-09-16 |
| GR3036368T3 (en) | 2001-11-30 |
| WO1993019061A1 (en) | 1993-09-30 |
| DE69330248D1 (de) | 2001-06-28 |
| KR100243534B1 (ko) | 2000-03-02 |
| AU3632493A (en) | 1993-10-21 |
| NO943450D0 (no) | 1994-09-16 |
| DK0631578T3 (da) | 2001-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE201408T1 (de) | Itraconazol- und saperconazolstereoisomere | |
| FI973518A7 (fi) | Piperidinoalkanoliyhdistettä tai sen farmaseuttisesti hyväksyttävää suolaa sisltävä farmaseuttinen koostumus kiinteässä yksikköannosmuodossa | |
| MX9505182A (es) | Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p. | |
| CA2426703A1 (en) | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | |
| UA50719C2 (uk) | Проліки для терапії пухлин і запальних захворювань | |
| CA2095223A1 (en) | Topical compositions for transdermal delivery of prodrug derivatives of morphine | |
| MY118526A (en) | Method for improving the pharmacokinetics of tipranavir | |
| NO994165L (no) | Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet | |
| GR3015014T3 (en) | Compositions for topical administration containing fluticasone propionate and oxiconazole or its salts. | |
| TR199900661T2 (xx) | Cilt enfeksiyonlar�n�n tedavisi amac�yla 1-hidroksi-2-piridonlar�n kullan�m� | |
| MX9504023A (es) | Composicion farmaceutica y transdermicamente activa que contiene acido 5-aminolaevulinico y procedimiento para su preparacion. | |
| ES2183220T3 (es) | Curacion de heridas y tratamientos de la fibrosis. | |
| RU94041028A (ru) | Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция | |
| RU94040886A (ru) | Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция | |
| GB9509888D0 (en) | Terpenoidic derivatives useful as antitumour agents | |
| US5798392C1 (en) | Sulfonyl fluorides for the treatment of alzheimer's disease | |
| CA2218643A1 (en) | Oral pharmaceutical composition of piperidinoalkanol compounds in solution form | |
| AU1898792A (en) | Treatment or therapeutic booth for energetic, cosmetic and medical purposes | |
| RU94040865A (ru) | Производные пептида и их терапевтически приемлемые соли, способ их получения, фармацевтическая и косметическая композиция с антивирусной активностью | |
| ATE238286T1 (de) | Neue triazole als therapeutische mittel gegen pilzinfektionen | |
| NZ328198A (en) | a pharmaceutical composition containing hydroxyzine and a serotonin uptake inhibitor | |
| BR0014751A (pt) | Composto, estereoisÈmero ou mistura de estereoisÈmeros, composição farmacêutica, método de tratamento de um paciente em necessidade de tratamento antimicrobiano, e, uso de um composto | |
| UA41326C2 (uk) | Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань | |
| TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
| HUP9801596A3 (en) | Use of azole compounds for preparing pharmaceutical compositions useful for the treatment of fungal infections, new azole derivatives and pharmaceutical compositions containing them |